Shanghai Labway Clinical Laboratory Co

Shanghai Labway Clinical Laboratory Co PEG

The PEG Ratio (Price/Earnings-to-Growth) of Shanghai Labway Clinical Laboratory Co (301060.SZ) as of Nov 2, 2026 is -2.03. In the previous year, PEG Ratio (Price/Earnings-to-Growth) was -1.53 — a change of 33.09% (lower).

PEG

-2.03

YoY

33.09%

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Shanghai Labway Clinical Laboratory Co is 2025 -2.03 . PEG Ratio (Price/Earnings-to-Growth) of Shanghai Labway Clinical Laboratory Co was 2024 -1.53 . It decreases by 33.09% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai Labway Clinical Laboratory Co Stock analysis

What does Shanghai Labway Clinical Laboratory Co do? Shanghai Labway Clinical Laboratory Co., Ltd. generates revenue through medical and pathological examination services, including pathological diagnosis, molecular examination, biochemical examination, immune examination, microbial examination, clinical basic examination, and physical and chemical examination. The company also sells in vitro diagnostic instruments, reagents, and related accessories and consumables. Its primary customers are healthcare providers and medical institutions requiring diagnostic services and diagnostic products. The business segments are medical testing services and in vitro diagnostic product sales. The company's medical testing services cater to hospitals and clinics seeking comprehensive diagnostic solutions, while the in vitro diagnostic product sales target healthcare facilities needing equipment and supplies for laboratory operations. These services and products are provided to clients across China, focusing on the healthcare sector's demand for accurate and timely diagnostic capabilities. Shanghai Labway's revenue streams are derived from both service fees for examinations and sales of diagnostic instruments and reagents. The company's offerings align with the growing need for advanced medical diagnostics in China's expanding healthcare market, serving a broad client base within the medical industry. Shanghai Labway Clinical Laboratory Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai Labway Clinical Laboratory Co stock

PEG Ratio (Price/Earnings-to-Growth) of Shanghai Labway Clinical Laboratory Co is -2.03 in 2025.

PEG Ratio (Price/Earnings-to-Growth) of Shanghai Labway Clinical Laboratory Co changed from -1.53 to -2.03, representing a 33.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Shanghai Labway Clinical Laboratory Co since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Shanghai Labway Clinical Laboratory Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Shanghai Labway Clinical Laboratory Co

All Key Metrics — Shanghai Labway Clinical Laboratory Co